These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33067810)

  • 1. Automated radiosynthesis of [
    Wichmann CW; Ackermann U; Poniger S; Young K; Nguyen B; Chan G; Sachinidis J; Scott AM
    J Labelled Comp Radiopharm; 2021 Mar; 64(3):140-146. PubMed ID: 33067810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel [
    Wang R; Jin W; Luo Y; Hong H; Zhao R; Li L; Yan L; Qiao J; Ploessl K; Zhu L; Kung HF
    Mol Pharm; 2024 Jul; 21(7):3256-3267. PubMed ID: 38856975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated synthesis of
    Sørensen MA; Andersen VL; Hendel HW; Vriamont C; Warnier C; Masset J; Huynh THV
    J Labelled Comp Radiopharm; 2020 Jun; 63(8):393-403. PubMed ID: 32374450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of [
    Kleynhans J; Rubow S; le Roux J; Marjanovic-Painter B; Zeevaart JR; Ebenhan T
    J Labelled Comp Radiopharm; 2020 Nov; 63(13):553-563. PubMed ID: 32865290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "One Method to Label Them All": A Single Fully Automated Protocol for GMP-Compliant
    Fouillet J; Donzé C; Deshayes E; Santoro L; Rubira L; Fersing C
    Curr Radiopharm; 2024; 17(3):285-301. PubMed ID: 38424422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-Specific Membrane Antigen Radioligand Therapy Using
    Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
    J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, Labeling and Preclinical Evaluation of a Squaric Acid Containing PSMA Inhibitor Labeled with
    Greifenstein L; Engelbogen N; Lahnif H; Sinnes JP; Bergmann R; Bachmann M; Rösch F
    ChemMedChem; 2020 Apr; 15(8):695-704. PubMed ID: 32057189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
    Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
    J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of
    Rodnick ME; Sollert C; Stark D; Clark M; Katsifis A; Hockley BG; Parr DC; Frigell J; Henderson BD; Bruton L; Preshlock S; Abghari-Gerst M; Piert MR; Fulham MJ; Eberl S; Gagnon K; Scott PJH
    Nat Protoc; 2022 Apr; 17(4):980-1003. PubMed ID: 35246649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiochemistry and Preclinical PET Imaging of
    Gourni E; Del Pozzo L; Bartholomä M; Kiefer Y; T Meyer P; Maecke HR; Holland JP
    Mol Imaging; 2017; 16():1536012117737010. PubMed ID: 29098927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining Absorbed Doses of Indigenously Developed
    Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
    Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
    [No Abstract]   [Full Text] [Related]  

  • 14. Preparation of
    Guleria M; Amirdhanayagam J; Sarma HD; Rallapeta RP; Krishnamohan VS; Nimmagadda A; Ravi P; Patri S; Kalawat T; Das T
    Biomed Res Int; 2021; 2021():1555712. PubMed ID: 34845436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy.
    Santo G; Di Santo G; Zelger B; Virgolini I
    Nuklearmedizin; 2024 Jun; 63(3):219-220. PubMed ID: 38190993
    [No Abstract]   [Full Text] [Related]  

  • 16. A Hangover Under 177 Lu-PSMA-617 Therapy : A Red Flag for Brain 68 Ga-PSMA-11 PET/MRI?
    Poterszman N; Somme L; Bund C; Hutt E; Somme F
    Clin Nucl Med; 2024 Jun; 49(6):582-583. PubMed ID: 38389216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of [(68)Ga]PSMA-11 for PET-CT imaging using a manual synthesis module and organic matrix based (68)Ge/(68)Ga generator.
    Nanabala R; Anees MK; Sasikumar A; Joy A; Pillai MR
    Nucl Med Biol; 2016 Aug; 43(8):463-9. PubMed ID: 27231953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties.
    Hou H; Pan Y; Wang Y; Ma Y; Niu X; Sun S; Hou G; Tao W; Gao F
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2819-2832. PubMed ID: 38683349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Visually Calculated SUV
    Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L
    J Nucl Med; 2024 Jun; 65(6):904-908. PubMed ID: 38637137
    [No Abstract]   [Full Text] [Related]  

  • 20. Value of post-therapy
    Tuncel M; Telli T
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):114-117. PubMed ID: 28750750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.